Sanctuary Advisors LLC Purchases 143,743 Shares of Bristol-Myers Squibb (NYSE:BMY)

Sanctuary Advisors LLC grew its stake in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 81.2% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 320,676 shares of the biopharmaceutical company's stock after acquiring an additional 143,743 shares during the quarter. Sanctuary Advisors LLC's holdings in Bristol-Myers Squibb were worth $16,592,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in BMY. Reston Wealth Management LLC purchased a new stake in Bristol-Myers Squibb in the third quarter worth approximately $25,000. Hollencrest Capital Management boosted its stake in shares of Bristol-Myers Squibb by 61.3% in the 3rd quarter. Hollencrest Capital Management now owns 492 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 187 shares during the last quarter. Kennebec Savings Bank bought a new stake in shares of Bristol-Myers Squibb in the third quarter worth $28,000. Darwin Wealth Management LLC purchased a new stake in Bristol-Myers Squibb during the third quarter valued at $29,000. Finally, Valued Wealth Advisors LLC lifted its holdings in Bristol-Myers Squibb by 1,168.1% in the third quarter. Valued Wealth Advisors LLC now owns 596 shares of the biopharmaceutical company's stock valued at $31,000 after acquiring an additional 549 shares during the period. 76.41% of the stock is currently owned by institutional investors.

Insider Activity at Bristol-Myers Squibb

In related news, EVP Samit Hirawat purchased 1,830 shares of the firm's stock in a transaction that occurred on Friday, November 1st. The shares were bought at an average price of $54.67 per share, for a total transaction of $100,046.10. Following the acquisition, the executive vice president now owns 62,109 shares of the company's stock, valued at approximately $3,395,499.03. This represents a 3.04 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Phil M. Holzer sold 700 shares of Bristol-Myers Squibb stock in a transaction on Monday, November 4th. The stock was sold at an average price of $55.62, for a total transaction of $38,934.00. Following the transaction, the senior vice president now directly owns 11,760 shares of the company's stock, valued at $654,091.20. The trade was a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.09% of the stock is owned by insiders.

Bristol-Myers Squibb Price Performance

BMY traded down $0.69 during trading on Friday, hitting $55.59. 3,821,199 shares of the company traded hands, compared to its average volume of 14,018,675. The company has a debt-to-equity ratio of 2.83, a quick ratio of 1.09 and a current ratio of 1.24. The stock's 50-day simple moving average is $55.82 and its two-hundred day simple moving average is $49.17. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $61.08.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 EPS for the quarter, topping analysts' consensus estimates of $1.49 by $0.31. The company had revenue of $11.89 billion for the quarter, compared to the consensus estimate of $11.26 billion. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The firm's revenue for the quarter was up 8.4% on a year-over-year basis. During the same period in the previous year, the business earned $2.00 earnings per share. On average, sell-side analysts expect that Bristol-Myers Squibb will post 0.93 EPS for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, February 3rd. Investors of record on Friday, January 3rd will be given a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 4.46%. The ex-dividend date of this dividend is Friday, January 3rd. This is a boost from Bristol-Myers Squibb's previous quarterly dividend of $0.60. Bristol-Myers Squibb's payout ratio is currently -66.85%.

Analyst Ratings Changes

A number of equities research analysts have issued reports on BMY shares. Leerink Partnrs upgraded Bristol-Myers Squibb from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, November 12th. Daiwa Capital Markets upgraded shares of Bristol-Myers Squibb from a "neutral" rating to an "outperform" rating in a research report on Wednesday, November 13th. Bank of America reiterated a "neutral" rating and issued a $63.00 price target on shares of Bristol-Myers Squibb in a research report on Tuesday. Morgan Stanley boosted their price objective on shares of Bristol-Myers Squibb from $36.00 to $39.00 and gave the company an "underweight" rating in a research report on Tuesday, November 12th. Finally, BMO Capital Markets raised their target price on Bristol-Myers Squibb from $57.00 to $61.00 and gave the stock a "market perform" rating in a report on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, fourteen have given a hold rating, two have assigned a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, Bristol-Myers Squibb presently has a consensus rating of "Hold" and an average price target of $54.29.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.